Introduction: The inflammatory mechanisms of COVID-19 suggest that corticosteroids may be beneficial, but their benefits must outweigh their potential risks. The RECOVERY trial results suggest that dexamethasone 6 mg/day (but not other steroids) may confer mortality benefits on ventilated COVID-19 patients. Methods: This is a narrative review of the literature about the use of ciclesonide and dexamethasone for COVID-19 patients. Literature is being created rapidly and this review is offered as a state-of-the-science narration. Results: The SARS-CoV-2 virus is an RNA virus whose RNA is transcribed via open reading frames, making its elimination difficult. Coronaviruses have evolved multiple strategies for proteolytic activation of the spike; viral replication occurs entirely in the cytoplasm. In this connection, the RNA-cleaving endoribonuclease (NSP-15 also known as EndoU) may play a key role by facilitating viral double-stranded RNA recognition by the host’s macrophages. Furthermore, the virus is able to undergo RNA recombination rapidly, enabling it to evade host immunity and develop drug resistance. Ciclesonide is an inhaled corticosteroid that reduces lung inflammation and blocks the activity of specific kinases which may explain its anti-inflammatory effect. Dexamethasone is known to reduce mortality in ventilated COVID-19 patients. Discussion: Systemic corticosteroids were used in previous coronavirus epidemics (SARS and MERS) and pulmonary histology of these patients is similar to those in COVID-19 patients. Acute respiratory distress syndrome is the main cause of death in most COVID-19 infections and steroids may be effective in addressing that condition, brought on by cytokine storm. However, it should be noted that inhaled steroids likely have a narrower window for effect than systemic regimens. Conclusion: Dexamethasone has been proven to confer mortality benefits on ventilated COVID-19 patients and may be used with inhaled ciclesonide, which has few side effects and can be locally metabolized. Further study is needed.
Ye, Q., Wang, B. and Mao, J. (2020) The Pathogenesis and Treatment of the “Cytokine Storm” in COVID-19. Journal of Infection, 80, 607-613. https://doi.org/10.1016/j.jinf.2020.03.037
AminJafari, A. and Ghasemi, S. (2020) The Possible of Immunotherapy for Covid-19: A Systematic Review. International Immunopharmacology, 83, Article ID: 106455. https://doi.org/10.1016/j.intimp.2020.106455
Veronese, N., Demurtas, J., Yang, L., et al. (2020) Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Frontiers in Medicine, 7, 170. https://doi.org/10.3389/fmed.2020.00170
WHO (2020) Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report RECOVERY Collaborative Group.
Shultz, M. (2007) Comparing Test Searches in PubMed and Google Scholar. Journal of the Medical Library Association, 95, 442-445. https://doi.org/10.3163/1536-5050.95.4.442
Henderson, J. (2005) Google Scholar: A Source for Clinicians? CMAJ, 172, 1549-1550. https://doi.org/10.1503/cmaj.050404
Mesel-Lemoine, M., Millet, J., Vidalain, P.-O., et al. (2012) A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes. Journal of Virology, 86, 7577-7587. https://doi.org/10.1128/JVI.00269-12
Masters, P.S. (2006) The Molecular Biology of Coronaviruses. Advances in Virus Research, 65, 193-292. https://doi.org/10.1016/S0065-3527(06)66005-3
Wang, H., Li, X., Li, T., et al. (2020) The Genetic Sequence, Origin, and Diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology and Infectious Diseases, 39, 1629-1635. https://doi.org/10.1007/s10096-020-03899-4
Kuljic-Kapulica, N. and Budisin, A. (1992) Coronaviruses. Srpski Arhiv za Celokupno Lekarstvo, 120, 215-218.
Stancioiu, F., Papadakis, G.Z., Kteniadakis, S., Izotov, B.N., Coleman, M.D., Spandidos, D.A. and Tsatsakis, A. (2020) A Dissection of SARS-CoV2 with Clinical Implications (Review). International Journal of Molecular Medicine, 489-508. https://doi.org/10.3892/ijmm.2020.4636 https://www.spandidos-publications.com/ijmm/46/2/489
Ziebuhr, J. (2004) Molecular Biology of Severe Acute Respiratory Syndrome Coronavirus. Current Opinion in Microbiology, 7, 412-419. https://doi.org/10.1016/j.mib.2004.06.007
Totura, A.L. and Bavari, S. (2019) Broad-Spectrum Coronavirus Antiviral Drug Discovery. Expert Opinion on Drug Discovery, 14, 397-412. https://doi.org/10.1080/17460441.2019.1581171
Millet, J.K. and Whittaker, G.R. (2015) Host Cell Proteases: Critical Determinants of Coronavirus Tropism and Pathogenesis. Virus Research, 202, 120-134. https://doi.org/10.1016/j.virusres.2014.11.021
Snijder, E.J., Decroly, E. and Zeibuhr, J. (2016) The Nonstrucutral Proteins Directing Coronavirus RNA Synthesis and Processing. In: Advances in Virus Research, Vol. 96, Academic Press, Cambridge, MA, 59-126. https://doi.org/10.1016/bs.aivir.2016.08.008
Hagemeijer, M.C., Verheije, M.H., Ulasli, M., et al. (2010) Dynamics of Coronavirus Replication-Transcription Complexes. Journal of Virology, 84, 2134-2149. https://doi.org/10.1128/JVI.01716-09
Mousavizadeh, L. and Ghasemi, S. (2020) Genotype and Phenotype of COVID-19: Their Roles in Pathogenesis. Journal of Microbiology, Immunology and Infection, in press. https://doi.org/10.1016/j.jmii.2020.03.022
Kim, Y., Jedrzejczak, R., Maltseva, N.I., et al. (2020) Crystal Structure of Nsp15 Endoribonuclease NendoU from SARS-CoV-2. Protein Science, 29, 1596-1605. https://doi.org/10.1002/pro.3873
Fehr, A.R. and Perlman, S. (2015) Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier, H., Bickerton, E. and Britton, P. (Eds.), Coronaviruses: Methods and Protocols, Springer, New York, 1-23. https://doi.org/10.1007/978-1-4939-2438-7_1
Wu, C., Liu, Y., Yang, Y., et al. (2020) Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. Acta Pharmaceutica Sinica B, 10, 766-788. https://doi.org/10.1016/j.apsb.2020.02.008
Neuman, B.W., Chamberlain, P., Bowden, F. and Joseph, J. (2014) Atlas of Coronavirus Replicase Structure. Virus Research, 194, 49-66. https://doi.org/10.1016/j.virusres.2013.12.004
Guarino, L.A., Bhardwaj, K., Dong, W., Sun, J., Holzenburg, A. and Kao, C. (2005) Mutational Analysis of the SARS Virus Nsp15 Endoribonuclease: Identification of Residues Affecting Hexamer Formation. Journal of Molecular Biology, 353, 1106-1117. https://doi.org/10.1016/j.jmb.2005.09.007
Zhang, L., Li, L., Yan, L., et al. (2018) Structural and Biochemical Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 92, e00893-18.
Joseph, J.S., Saikatendu, K.S., Subramanian, V., et al. (2007) Crystal Structure of a Monomeric Form of Severe Acute Respiratory Syndrome Coronavirus Endonuclease nsp15 Suggests a Role for Hexamerization as an Allosteric Switch. Journal of Virology, 81, 6700-3708. https://doi.org/10.1128/JVI.02817-06
Bhardwaj, K., Sun, J., Holzenburg, A., Guarino, L.A. and Kao, C.C. (2006) RNA Recognition and Cleavage by the SARS Coronavirus Endoribonuclease. Journal of Molecular Biology, 361, 243-256. https://doi.org/10.1016/j.jmb.2006.06.021
Bhardwaj, K., Guarino, L. and Kao, C.C. (2004) The Severe Acute Respiratory Syndrome Coronavirus Nsp15 Protein Is an Endoribonuclease That Prefers Manganese as a Cofactor. Journal of Virology, 78, 12218-12224. https://doi.org/10.1128/JVI.78.22.12218-12224.2004
Deng, X. and Baker, S.C. (2018) An “Old” Protein with a New Story: Coronavirus Endoribonuclease Is Important for Evading Host Antiviral Defenses. Virology, 517, 157-163. https://doi.org/10.1016/j.virol.2017.12.024
Deng, X., Hackbart, M., Mettelman, R.C., et al. (2017) Coronavirus Nonstructural Protein 15 Mediates Evasion of dsRNA Sensors and Limits Apoptosis in Macrophages. Proceedings of the National Academy of Sciences of the United States of America, 114, E4251-E4260. https://doi.org/10.1073/pnas.1618310114
Duffy, S. (2018) Why Are RNA Virus Mutation Rates So Damn High? PLoS Biology, 16, E4251-E4260. https://doi.org/10.1371/journal.pbio.3000003
Pachetti, M., Marini, B., Benedetti, F., et al. (2020) Emerging SARS-CoV-2 Mutation Hot Spots Include a Novel RNA-Dependent-RNA Polymerase Variant. Journal of Translational Medicine, 18, Article No. 179. https://doi.org/10.1186/s12967-020-02344-6
Sanjuán, R. and Domingo-Calap, P. (2016) Mechanisms of Viral Mutation. Cellular and Molecular Life Sciences, 73, 4433-4448. https://doi.org/10.1007/s00018-016-2299-6
Regoes, R.R., Hamblin, S. and Tanaka, M.M. (2013) Viral Mutation Rates: Modelling the Roles of Within-Host Viral Dynamics and the Trade-Off between Replication Fidelity and Speed. Proceedings of the Royal Society B: Biological Sciences, 280, Article ID: 20122047. https://doi.org/10.1098/rspb.2012.2047
Eckerle, L.D., Becker, M.M., Halpin, R.A., et al. (2010) Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing. PLoS Pathogens, 6, e1000896. https://doi.org/10.1371/journal.ppat.1000896
Hadfield, J., Megill, C., Bell, S.M., et al. (2018) NextStrain: Real-Time Tracking of Pathogen Evolution. Bioinformatics, 34, 4121-4123. https://doi.org/10.1093/bioinformatics/bty407
Day, T., Gandon, S., Lion, S. and Otto, S.P. (2020) On the Evolutionary Epidemiology of SARS-CoV-2. Current Biology, 30, R849-R857. https://doi.org/10.1016/j.cub.2020.06.031
Korber, B., Fischer, W.M., Gnanakaran, S., et al. (2020) Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. Cell, 182, 812-827.E19. https://doi.org/10.1016/j.cell.2020.06.043
Yin, W., Mao, C., Luan, X., et al. (2020) Structural Basis for Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir. Science, 368, 1499-1504. https://pubmed.ncbi.nlm.nih.gov/32358203/
RECOVERY and RemdesivirV1.0 2020-05-27. https://www.recoverytrial.net/
Maruta, H. (2014) Herbal Therapeutics That Block the Oncogenic Kinase PAK1: A Practical Approach towards PAK1-Dependent Diseases and Longevity. Phytotherapy Research, 28, 656-672. https://doi.org/10.1002/ptr.5054
Zhao, Z. and Manser, E. (2012) PAK Family Kinases. Cellular Logistics, 2, 59-68. https://doi.org/10.4161/cl.21912
Maruta, H. and He, H. (2020) PAK1-Blockers: Potential Therapeutics against COVID-19. Medicine in Drug Discovery, 6, Article ID: 100039. https://doi.org/10.1016/j.medidd.2020.100039
Demestre, M., Messerli, S.M., Celli, N., et al. (2009) CAPE (Caffeic Acid Phenethyl Ester)-Based Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice. Phytotherapy Research, 23, 226-230. https://doi.org/10.1002/ptr.2594
Wang, M., Cao, R., Zhang, L., et al. (2020) Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. Cell Research, 30, 269-271. https://doi.org/10.1038/s41422-020-0282-0
Chen, I.-Y., Chang, S.C., Wu, H.-Y., et al. (2010) Upregulation of the Chemokine (C-C Motif) Ligand 2 via a Severe Acute Respiratory Syndrome Coronavirus Spike-ACE2 Signaling Pathway. Journal of Virology, 84, 7703-7712. https://doi.org/10.1128/JVI.02560-09
Matsuyama, S., Kawase, M., Nao, N., et al. (2020) The Inhaled Corticosteroid Ciclesonide Blocks Coronavirus RNA Replication by Targeting Viral NSP15.
Fuller, P.J., Lim-Tio, S.S. and Brennan, F.E. (2000) Specificity in Mineralocorticoid versus Glucocorticoid Action. Kidney International, 57, 1256-1264. https://doi.org/10.1046/j.1523-1755.2000.00959.x
Stockman, L.J., Bellamy, R. and Garner, P. (2017) SARS: Systematic Review of Treatment Effects. PLoS ONE, 12, e343.
Ramadan, A.A., Gaffin, J.M., Israel, E. and Phipatanakul, W. (2019) Asthma and Corticosteroid Responses in Childhood and Adult Asthma. Clinics in Chest Medicine, 40, 163-177. https://doi.org/10.1016/j.ccm.2018.10.010
Morra, M.E., van Thanh, L., Kamel, M.G., et al. (2018) Clinical Outcomes of Current Medical Approaches for Middle East Respiratory Syndrome: A Systematic Review and Meta-Analysis. Reviews in Medical Virology, 28, e1977. https://doi.org/10.1002/rmv.1977
van der Velden, V.H.J. (1998) Glucocorticoids: Mechanisms of Action and Anti-Inflammatory Potential in Asthma. Mediators in Inflammation, 7, Article ID: 702547. https://doi.org/10.1080/09629359890910
Zhang, W., Zhao, Y., Zhang, F., et al. (2020) The Use of Anti-Inflammatory Drugs in the Treatment of People with Severe Coronavirus Disease 2019 (COVID-19): The Experience of Clinical Immunologists from China. Clinical Immunology, 214, Article ID: 108393. https://doi.org/10.1016/j.clim.2020.108393
Xu, Z., Shi, L., Wang, Y., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
Rochwerg, B., Oczkowski, S.J., Siemieniuk, R.A.C., et al. (2018) Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Critical Care Medicine, 46, 1411-1420. https://doi.org/10.1097/CCM.0000000000003262
Villar, J., Ferrando, C., Martínez, D., et al. (2020) Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial. The Lancet Respiratory Medicine, 8, 267-276. https://doi.org/10.1016/S2213-2600(19)30417-5
Hardeman, H., Grutters, J.C., van de Garde, M.W., et al. (2011) Dexamethasone and Length of Hospital Stay in Patients with Community-Acquired Pneumonia: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 377, 2023-2053. https://doi.org/10.1016/S0140-6736(11)60607-7
Annane, D., Bellissant, E., Bollaert, P.-E., et al. (2009) Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults: A Systematic Review. JAMA, 301, 2362-2375. http://www.bireme.br
Stein, S.W. and Thiel, C.G. (2017) The History of Therapeutic Aerosols: A Chronological Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 30, 20-41. https://doi.org/10.1089/jamp.2016.1297
Christie, P. (2004) Ciclesonide: A Novel Inhaled Corticosteroid for Asthma. Drugs of Today, 40, 569-576. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=4&p_RefId=850475&p_IsPs=N
Nave, R., Bethke, T.D., van Marle, S.P. and Zech, K. (2004) Pharmacokinetics of [14C]Ciclesonide after Oral and Intravenous Administration to Healthy Subjects. Clinical Pharmacokinetics, 43, 479-486. https://doi.org/10.2165/00003088-200443070-00004
Nave, R., Watz, H., Hoffmann, H., Boss, H. and Magnussen, H. (2010) Deposition and Metabolism of Inhaled Ciclesonide in the Human Lung. European Respiratory Journal, 36, 1113-1119. https://doi.org/10.1183/09031936.00172309
Jeon, S., Ko, M., Lee, J., et al. (2020) Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrobial Agents and Chemotherapy, 64, e00819-20.
Choi, H.S., Kim, S.L., Kim, J.H. and Lee, D.S. (2020) The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation. International Journal of Molecular Sciences, 21, 1014. https://doi.org/10.3390/ijms21031014
Allen, J.D., Jaffer, Z.M., Park, S.J., et al. (2009) P21-Activated Kinase Regulates Mast Cell Degranulation via Effects on Calcium Mobilization and Cytoskeletal Dynamics. Blood, 113, 2695-2705. https://doi.org/10.1182/blood-2008-06-160861
Vogelmeier, C.F., Hering, T., Lewin, T., Sander, P. and Bethke, T.D. (2011) Efficacy and Safety of Ciclesonide in the Treatment of 24,037 Asthmatic Patients in Routine Medical Care. Respiratory Medicine, 105, 186-194. https://doi.org/10.1016/j.rmed.2010.09.016
Derendorf, H. (2007) Therapeutic Review: Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide. Journal of Clinical Pharmacology, 47, 782-789. https://doi.org/10.1177/0091270007299763
Halpin, D.M.G., Faner, R., Sibila, O., Badia, J.R. and Agusti, A. (2020) Do Chronic Respiratory Diseases or Their Treatment Affect the Risk of SARS-CoV-2 Infection? The Lancet Respiratory Medicine, 8, 436-438. https://doi.org/10.1016/S2213-2600(20)30167-3
Mahdavinia, M., Foster, K.J., Jauregui, E., et al. (2020) Asthma Prolongs Intubation in COVID-19. The Journal of Allergy and Clinical Immunology: In Practice, 8, 2388-2391. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224651/
Johnston, S.L. (2005) Overview of Virus-Induced Airway Disease. Proceedings of the American Thoracic Society, 2, 150-156.
Wu, C., Chen, X., Cai, Y., et al. (2020) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180, 934-943. https://doi.org/10.1001/jamainternmed.2020.0994
Kurai, D., Saraya, T., Ishii, H. and Takizawa, H. (2013) Virus-Induced Exacerbations in Asthma and COPD. Frontiers in Microbiology, 4, 293. https://doi.org/10.3389/fmicb.2013.00293
Yang, I.A., Clarke, M.S., Sim, E.H. and Fong, K.M. (2012) Inhaled Corticosteroids for Stable Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, No. 7, CD002991. https://doi.org/10.1002/14651858.CD002991.pub3
Contoli, M., Pauletti, A., Rossi, M.R., et al. (2017) Long-Term Effects of Inhaled Corticosteroids on Sputum Bacterial and Viral Loads in COPD. European Respiratory Journal, 50, Article ID: 1700451. https://doi.org/10.1183/13993003.00451-2017
Schaller, T., Hirschbühl, K., Burkhardt, K., et al. (2020) Postmortem Examination of Patients with COVID-19. JAMA, 323, 2518-2520. https://doi.org/10.1001/jama.2020.8907
van den Brand, J.M.A., Smits, S.L. and Haagmans, B.L. (2015) Pathogenesis of Middle East Respiratory Syndrome Coronavirus. Journal of Pathology, 235, 175-184. https://doi.org/10.1002/path.4458
Ito, K., Ohmagari, N., Mikami, A. and Sugiura, W. (2020) Major Ongoing Clinical Trials for COVID-19 Treatment and Studies Currently Being Conducted or Scheduled in Japan. Global Health & Medicine, 2, 96-101. https://doi.org/10.35772/ghm.2020.01034
Gralinski, L.E., Sheahan, T.P., Morrison, T.E., et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio, 9, e01753-18. https://doi.org/10.1128/mBio.01753-18
Zhong, J., Tang, J., Ye, C. Dong, L. (2020) The Immunology of COVID-19: Is Immune Modulation an Option for Treatment? The Lancet Rheumatology, 2, E428-E436. https://doi.org/10.1016/S2665-9913(20)30120-X
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. The Lancet, 395, 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Nakajima, K., Ogawa, F., Sakai, K., et al. (2020) A Case of Coronavirus Disease 2019 Treated with Ciclesonide. Mayo Clinic Proceedings, 95, 1296-1297. https://doi.org/10.1016/j.mayocp.2020.04.007
Ito, K., Yokoyama, T., Oguri, A., et al. (2020) Case Report: A Case of COVID-19 Pneumonia That Did Not Worsen and Was Relieved by Early Administration of Favipiravir and Ciclesonide.
(2020) A Trial of Ciclesonide in Adults with Mild COVID-19. Clinical-Trials.gov. https://clinicaltrials.gov/ct2/show/NCT04330586
Iwabuchi, K., Yoshie, K., Kurakami, Y., Takahashi, K., Kato, Y. and Morishima, T. (2020) Therapeutic Potential of Ciclesonide Inhalation for COVID-19 Pneumonia: Report of Three Cases. Journal of Infection and Chemotherapy, 26, 625-632. https://doi.org/10.1016/j.jiac.2020.04.007
Al-Dorzi, H.M., al Harbi, S.A. and Arabi, Y.M. (2014) Antibiotic Therapy of Pneumonia in the Obese Patient: Dosing and Delivery. Current Opinion in Infectious Diseases, 27, 165-173. https://doi.org/10.1097/QCO.0000000000000045
Iannella, H., Luna, C. and Waterer, G. (2016) Inhaled Corticosteroids and the Increased Risk of Pneumonia: What’s New? A 2015 Updated Review. Therapeutic Advances in Respiratory Disease, 10, 235-255. https://doi.org/10.1177/1753465816630208
Spagnolo, P., Balestro, E., Aliberti, S., et al. (2020) Pulmonary Fibrosis Secondary to COVID-19: A Call to Arms? The Lancet Respiratory Medicine, 8, 750-752. https://doi.org/10.1016/S2213-2600(20)30222-8
Stein, R., Sherril, D.L., Morgan, W.J., Holberg, C.J., Halonen, M., Taussig, L., Wright, A. and Martinez, F.D. (1999) Respiratory Syncytial Virus in Early Life and Risk of Wheeze and Allergy by Age 13 Years. The Lancet, 354, 541-545. https://www.sciencedirect.com/science/article/pii/S0140673698103215 https://doi.org/10.1016/S0140-6736(98)10321-5
Woods, J.A., Wheeler, J.S., Finch, C.K. and Pinner, N.A. (2014) Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of COPD, 9, 421-430. https://doi.org/10.2147/COPD.S51012